Roivant's mosliciguat posts standout Phase 2 win in pulmonary hypertension linked to lung disease

Roivant Sciences and its subsidiary Pulmovant reported positive topline results on 8 September 2026 from the Phase 2 PHocus study of mosliciguat, an inhaled drug for pulmonary hypertension associated with interstitial lung disease (PH-ILD) — a condition where scarring of the lungs raises blood pressure in the arteries feeding them, straining the heart and leaving patients breathless with few good treatment options.

In the 16-week, placebo-controlled trial of 135 patients, mosliciguat cut pulmonary vascular resistance — a measure of how hard the heart must pump blood through the lungs — by 56% versus placebo, one of the largest reductions reported in a pulmonary hypertension trial to date. The company said it was surprised by the size of the effect. Mosliciguat is delivered directly to the lungs by inhaler and works by activating an enzyme that relaxes and widens blood vessels, easing the pressure.

The result sent Roivant's shares up nearly 19% on the day and sets up a move into late-stage development. The data were presented at the European Respiratory Society (ERS) Congress 2026.

Source: STAT News, 8 September 2026.